Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-05-10-Speech-4-314-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-05-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20120510.69.4-314-500"2
lpv:hasSubsequent	lp_eu:2012-05-10-Speech-4-314-6252
lpv:speaker	lp:Luís Paulo Alves2
lpv:spokenAs	unknown; Partido Socialista (2009-07-14--2014-06-30)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 member; REGI (2012-01-19--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; AGRI (2012-01-19--2014-06-30)3
lpv:translated text	"I am voting for this report, principally because the management board adopted limitations on the subsequent professional activities of the former executive director, following public protest supported by Parliament regarding its decision in January 2011 to authorise his new activities fully. I would highlight the fact that the parliamentary committee held an exchange of views with the executive director-designate in July 2011 where the issue was addressed again in order to avoid future recurrences. I regret that in its follow-up report of September 2010, the Internal Audit Service continued to find the assessment of experts’ independence inadequate, and it is essential that the executive director publish a list of all the authorised medicinal products concerned and report how the agency intends to rectify those procedures."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph